SG10201510152RA - Diagnostic methods and compositions for treatment of cancer - Google Patents
Diagnostic methods and compositions for treatment of cancerInfo
- Publication number
- SG10201510152RA SG10201510152RA SG10201510152RA SG10201510152RA SG10201510152RA SG 10201510152R A SG10201510152R A SG 10201510152RA SG 10201510152R A SG10201510152R A SG 10201510152RA SG 10201510152R A SG10201510152R A SG 10201510152RA SG 10201510152R A SG10201510152R A SG 10201510152RA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- compositions
- treatment
- diagnostic methods
- diagnostic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22512009P | 2009-07-13 | 2009-07-13 | |
| US35173310P | 2010-06-04 | 2010-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201510152RA true SG10201510152RA (en) | 2016-01-28 |
Family
ID=43227992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012002432A SG177640A1 (en) | 2009-07-13 | 2010-07-12 | Diagnostic methods and compositions for treatment of cancer |
| SG10201510152RA SG10201510152RA (en) | 2009-07-13 | 2010-07-12 | Diagnostic methods and compositions for treatment of cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012002432A SG177640A1 (en) | 2009-07-13 | 2010-07-12 | Diagnostic methods and compositions for treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110076271A1 (en) |
| EP (1) | EP2454380A2 (en) |
| JP (2) | JP6095367B2 (en) |
| KR (1) | KR20120106935A (en) |
| CN (2) | CN102482715A (en) |
| AU (1) | AU2010273585B2 (en) |
| BR (1) | BR112012000735A2 (en) |
| CA (1) | CA2766403A1 (en) |
| HK (1) | HK1226108A1 (en) |
| IL (1) | IL216926A0 (en) |
| MX (1) | MX2012000620A (en) |
| SG (2) | SG177640A1 (en) |
| WO (1) | WO2011008696A2 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011153224A2 (en) * | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| WO2012151574A1 (en) | 2011-05-05 | 2012-11-08 | Duke University | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
| EP2798081A1 (en) * | 2011-12-29 | 2014-11-05 | Baylor Research Institute | Biomarkers for kawasaki disease |
| AU2013207778B2 (en) | 2012-01-13 | 2017-10-12 | Genentech, Inc. | Biological markers for identifying patients for treatment with VEGF antagonists |
| CA2867588A1 (en) * | 2012-03-30 | 2013-10-03 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| MX2014014821A (en) * | 2012-06-26 | 2015-02-12 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer. |
| WO2014058915A2 (en) | 2012-10-08 | 2014-04-17 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| MX2016000172A (en) * | 2013-07-23 | 2016-03-09 | Genentech Inc | Model of colorectal cancer. |
| CN103911451A (en) * | 2014-04-11 | 2014-07-09 | 蒋晓东 | Method for screening lung cancer target people for anti-angiogenesis targeted drug therapy |
| CN107076750B (en) * | 2014-07-18 | 2020-06-23 | 赛诺菲 | Method for predicting the outcome of a treatment with aflibercept in a patient suspected of having cancer |
| US10364289B2 (en) * | 2014-12-03 | 2019-07-30 | Samsung Life Public Welfare Foundation | Antibody binding to neuropilin 1 and use thereof |
| WO2017066659A1 (en) * | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Jag1 expression predicts therapeutic response in nash |
| CN110087676A (en) * | 2016-03-29 | 2019-08-02 | 巴黎大学迪德罗特第七分校 | The composition of the extracellular vesica of secretory of the cell comprising expression NFATC4 for treating cancer |
| AU2017248766A1 (en) * | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
| US11499973B2 (en) | 2016-05-17 | 2022-11-15 | Duke University | Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer |
| EP3467508A4 (en) * | 2016-06-03 | 2020-04-29 | Samsung Life Public Welfare Foundation | Anti-nrp1 antibody screening method |
| CN106282376A (en) * | 2016-09-27 | 2017-01-04 | 上海交通大学医学院附属第九人民医院 | A kind of antisense RNA probes for detecting BMP9 gene expression |
| WO2018127599A1 (en) * | 2017-01-09 | 2018-07-12 | Secarna Pharmaceuticals Gmbh & Co Kg | Oligonucleotides inhibiting the expression of nrp1 |
| CA3052670A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN109828114A (en) * | 2017-11-23 | 2019-05-31 | 复旦大学附属肿瘤医院 | MFAP5 albumen is as the method and application in the kit of screening interferon alfa liver cancer sensitive group |
| CN109828111A (en) * | 2017-11-23 | 2019-05-31 | 复旦大学附属肿瘤医院 | Purposes of the MFAP5 in the preparation that preparation screening alpha interferon intervenes liver cancer sensitive group marker |
| BR112021002728A2 (en) * | 2018-08-17 | 2021-08-10 | F. Hoffmann-La Roche Ag | methods of evaluating atrial fibrillation, aiding in the evaluation of atrial fibrillation, diagnosing heart failure and predicting the risk of hospitalization, computer-implemented method for evaluating atrial fibrillation, kit and in vitro uses |
| CN110893238A (en) * | 2018-09-13 | 2020-03-20 | 常州大学 | Application of substance for inhibiting activity and expression quantity of vascular endothelial growth factor in preparation of product for inhibiting lymph node metastasis |
| BR112021004329A2 (en) | 2018-10-23 | 2021-08-03 | Regeneron Pharmaceuticals, Inc. | anti-npr1 antibodies and their uses |
| CN112213495B (en) * | 2020-09-18 | 2022-10-28 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) | Marker for auxiliary diagnosis or diagnosis of femoral head necrosis |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| JP3068180B2 (en) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | Generation of heterologous antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| BR9207175A (en) | 1992-10-28 | 1995-12-12 | Genentech Inc | Composition containing vascular endothelial cell growth factor antagonist polypeptide monoclonal antibody amino acid sequence and method of treatment of tumor in mammal |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU710696C (en) | 1995-09-08 | 2002-10-24 | Genentech Inc. | VEGF-related protein |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR100489174B1 (en) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-anilinoquinazoline derivatives |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| BR9710362A (en) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound |
| KR20080059467A (en) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| AU740738B2 (en) | 1997-04-07 | 2001-11-15 | Genentech Inc. | Humanized antibodies and methods for forming humanized antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| TR199903123T2 (en) | 1997-04-07 | 2000-05-22 | Genentech, Inc. | Anti-Vegf antikorlar�. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
| DE69838172T2 (en) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER |
| JP2001518470A (en) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | Novel angiogenesis inhibitors |
| JP2001522853A (en) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| DK1034298T3 (en) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanization of murine antibody |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| WO1999061422A1 (en) | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| UA60365C2 (en) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
| WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| JP2003529774A (en) | 2000-03-31 | 2003-10-07 | ジェネンテック・インコーポレーテッド | Compositions and methods for detecting and quantifying gene expression |
| US6998234B2 (en) * | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| KR100976076B1 (en) | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| RU2005136988A (en) | 2003-05-30 | 2006-06-10 | Дженентек, Инк. (Us) | ANTIBODY TREATMENT AGAINST VEGF |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| CN102895663A (en) * | 2004-04-14 | 2013-01-30 | 健泰科生物技术公司 | Compositions containing EGFL 7 antagonist for modulating vascular development and methods |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| JP2007070633A (en) | 2005-09-06 | 2007-03-22 | Lg Electronics Inc | Printing ink and fluorescent substance slurry composition, printer using the same and plasma display panel and method for producing the same |
| UA96139C2 (en) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
| ITRM20060337A1 (en) * | 2006-06-27 | 2007-12-28 | Biosoot Srl | GENE TEM8 (TUMOR ENDOTELIAL MARKER 8) AND ITS FORMS OF EXPRESSION AND DIAGNOSTIC AND THERAPEUTIC USE |
| WO2008128233A1 (en) * | 2007-04-15 | 2008-10-23 | University Of Chicago | Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr) |
| BRPI0817158A2 (en) * | 2007-11-09 | 2015-04-14 | Genentech Inc | "Method to Identify a Kidney Cancer Patient, Kit, Methods and Compound Set" |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
-
2010
- 2010-07-12 AU AU2010273585A patent/AU2010273585B2/en not_active Ceased
- 2010-07-12 KR KR1020127003607A patent/KR20120106935A/en not_active Application Discontinuation
- 2010-07-12 SG SG2012002432A patent/SG177640A1/en unknown
- 2010-07-12 SG SG10201510152RA patent/SG10201510152RA/en unknown
- 2010-07-12 MX MX2012000620A patent/MX2012000620A/en unknown
- 2010-07-12 CN CN2010800365602A patent/CN102482715A/en active Pending
- 2010-07-12 CN CN201610767315.8A patent/CN106148547A/en active Pending
- 2010-07-12 US US12/834,523 patent/US20110076271A1/en not_active Abandoned
- 2010-07-12 EP EP10731915A patent/EP2454380A2/en not_active Withdrawn
- 2010-07-12 WO PCT/US2010/041706 patent/WO2011008696A2/en active Application Filing
- 2010-07-12 CA CA2766403A patent/CA2766403A1/en not_active Abandoned
- 2010-07-12 BR BR112012000735A patent/BR112012000735A2/en not_active IP Right Cessation
- 2010-07-12 JP JP2012520702A patent/JP6095367B2/en not_active Expired - Fee Related
-
2011
- 2011-12-13 IL IL216926A patent/IL216926A0/en unknown
-
2012
- 2012-08-18 HK HK16114547A patent/HK1226108A1/en unknown
-
2013
- 2013-07-10 US US13/938,535 patent/US20140302056A2/en not_active Abandoned
-
2016
- 2016-12-28 JP JP2016255038A patent/JP2017099389A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010273585B2 (en) | 2015-04-23 |
| SG177640A1 (en) | 2012-02-28 |
| US20140302056A2 (en) | 2014-10-09 |
| WO2011008696A3 (en) | 2011-04-14 |
| JP6095367B2 (en) | 2017-03-15 |
| AU2010273585A1 (en) | 2012-01-19 |
| CA2766403A1 (en) | 2011-01-20 |
| MX2012000620A (en) | 2012-01-27 |
| CN106148547A (en) | 2016-11-23 |
| JP2012532628A (en) | 2012-12-20 |
| WO2011008696A2 (en) | 2011-01-20 |
| CN102482715A (en) | 2012-05-30 |
| EP2454380A2 (en) | 2012-05-23 |
| IL216926A0 (en) | 2012-02-29 |
| US20110076271A1 (en) | 2011-03-31 |
| US20140099326A1 (en) | 2014-04-10 |
| JP2017099389A (en) | 2017-06-08 |
| BR112012000735A2 (en) | 2016-11-16 |
| HK1226108A1 (en) | 2017-09-22 |
| KR20120106935A (en) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258794B (en) | Methods and compositions for diagnosis and treatment of cancer | |
| HK1226108A1 (en) | Diagnostic methods and compositions for treatment of cancer | |
| ZA201105472B (en) | Methods and compositions for diagnosis and treatment of cancer | |
| IL218575A0 (en) | Treatment of cancer | |
| EP2751570A4 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| HK1178074A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP2480687A4 (en) | Methods and compositions for the diagnosis and treatment of thyroid cancer | |
| HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
| ZA201006988B (en) | Method and compositions for treatment of cancer | |
| IL240560A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP2723924A4 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| EP2340027A4 (en) | Methods and compositions for the treatment of cancer | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| EP2437738A4 (en) | Methods and compositions for the treatment of cancer | |
| GB0902040D0 (en) | Composition for treatment of skin | |
| EP2515652A4 (en) | Compositions and methods for treatment of vitiligo | |
| EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
| EP2547368A4 (en) | Methods and compositions for the treatment of cancer | |
| GB0916686D0 (en) | Treatment of cancer | |
| GB201017857D0 (en) | Methods for diagnosis and methods of treatment | |
| GB0921757D0 (en) | Treatment of cancer |